Abstract

Background: Preeclampsia (PE) is a multi-systemic progressive disorder that is unique to human pregnancy, occurring usually after 20 weeks of gestation. Useful biochemical markers to be utilized for early prediction of preeclampsia continue to elude us. The search for biomarkers is aimed identifying women at increased risk of developing PE, so that medical interventions may be instituted very early in pregnancy to ameliorate its occurrence and improve maternal and fetal outcome.

Aim: This study aimed to determine the association between serum levels of Cystatin C and/or free β-subunit of hCG measured in early pregnancy and the development of pre-eclampsia and its severity.

Methods: This was a prospective cohort study of 290 pregnant women recruited during routine antenatal care, at the gestational age of between 13 and 19 weeks. After obtaining an informed consent from each participant, a structured questionnaire was used to collection relevant information followed by the collection of 5 mL of venous blood sample. Serum cystatin C and free subunit of β-hCG levels were determined by standard enzyme-linked immunosorbent assay (ELISA) method. All participants were followed up till delivery and those who developed preeclampsia was classified as mild and severe preeclampsia.

Data were entered and analyzed using STATA version 16 statistical software. Hypothesis testing was done using chi-square test for categorical variables, and the independent-samples t-test and ANOVA for numerical variables.

Results: We found significantly elevated serum levels of cystatin C and free subunit of β-hCG in women who developed preeclampsia, (p < 0.002 and 0.001) respectively.

Conclusion: Elevated serum levels of cystatin C and free serum beta hCG are predictive of development of preeclampsia and its severity.

Keywords: Cystatin C; Early Predictors; Free Β-hCG; Hypertension; Preeclampsia; Severity

References

1. Osanyin GE., et al. “Association between serum CA125 levels in preeclampsia and its severity among women in Lagos, South-West Nigeria”. Hypertension Pregnancy2 (2018): 93-97.
2. Poon LC., et al. “The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention”. International Journal of Gynecology and Obstetrics1 (2019): 1-33.
3. Abalos E., et al. “Global and regional estimates of preeclampsia and eclampsia: a systematic review”. European Journal of Obstetrics and Gynecology and Reproductive Biology 170 (2013): 1-14.
4. Babah OA., et al. “Prevalence and pattern of medical disorders in pregnancy at the time of delivery at Lagos University Teaching Hospital, Lagos, Nigeria”. Sub-Saharan African Journal of Medicine 5 (2018): 93-98.
5. Babah OA., et al. “Postpartum sequelae of the hypertensive diseases of pregnancy: A pilot study”. Journal of the Nigeria Medical Association 59 (2018): 1-6.
6. Park HJ., et al. “Combined Screening for Early Detection of Pre-Eclampsia”. International Journal of Molecular Sciences8 (2015): 17952-17974.
7. Thilaganathan B., et al. “Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia”. Reproductive Sciences8 (2009): 788-793.
8. Risch M., et al. “High first-trimester maternal blood cystatin C levels despite normal serum creatinine predict pre-eclampsia in singleton pregnancies”. Scandinavian Journal of Clinical and Laboratory Investigation8 (2017): 634-643.
9. Kanika MC., et al. “Value of Serum β-hCG in Pathogenesis of Pre-Eclampsia”. Clinical Obstetrics and Gynecology4-5 (2012): 71-75.
10. Wright A., et al. “Maternal serum PAPP-A and free β-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia”. Ultrasound in Obstetrics and Gynecology6 (2016): 762-767.
11. Begum Z., et al. “The Association between Serum Beta human Chorionic Gonadotropin and Preeclampsia”. Journal of Dhaka Medical College1 (2014): 89-93.
12. Padma Y., et al. “Renal markers in normal and hypertensive disorders of pregnancy in Indian women: a pilot study”. International Journal of Reproduction, Contraception, Obstetrics and Gynecology4 (2013): 514-520.
13. Tranquilli AL., et al. “The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP”. Pregnancy Hypertension2 (2014): 97-104.
14. Hypertension in pregnancy: NICE guideline (2019).
15. Wattanavaekin K., et al. “Cystatin C as a novel predictor of preterm labor in severe preeclampsia”. Kidney Research and Clinical Practice4 (2018): 338-346.
16. Spencer K., et al. “Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler”. Prenatal Diagnosis10 (2005): 949-953.
17. Barjaktarovic M., et al. “Human chorionic gonadotropin and risk of pre-eclampsia: prospective population-based cohort study”. Ultrasound in Obstetrics and Gynecology4 (2019): 477-483.
18. Ong CY., et al. “First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications”. BJOG: An International Journal of Obstetrics and Gynaecology10 (2000): 1265-1270.
19. Goetzinger KR., et al. “Predicting the risk of pre-eclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free β-hCG”. Prenatal Diagnosis 12-13 (2010): 1138-1142.
20. Murmu S and Dwivedi J. “Second-Trimester Maternal Serum Beta-Human Chorionic Gonadotropin and Lipid Profile as a Predictor of Gestational Hypertension, Preeclampsia, and Eclampsia: A Prospective Observational Study”. International Journal of Applied and Basic Medical Research1 (2020): 49-53.